QQQ   332.15 (-0.27%)
AAPL   172.76 (-0.25%)
MSFT   292.24 (-0.42%)
META   179.16 (-0.96%)
GOOGL   121.82 (-0.21%)
AMZN   144.93 (+1.22%)
TSLA   922.06 (-0.64%)
NVDA   188.87 (-0.76%)
NIO   20.91 (-1.83%)
BABA   92.83 (-1.45%)
AMD   99.89 (-1.11%)
MU   64.14 (-0.87%)
T   18.66 (+1.47%)
CGC   3.80 (-0.52%)
F   16.56 (+1.47%)
GE   80.19 (+0.48%)
DIS   125.25 (+0.80%)
AMC   24.77 (+2.31%)
PYPL   101.84 (+0.33%)
PFE   49.90 (+0.30%)
NFLX   246.64 (-0.99%)
QQQ   332.15 (-0.27%)
AAPL   172.76 (-0.25%)
MSFT   292.24 (-0.42%)
META   179.16 (-0.96%)
GOOGL   121.82 (-0.21%)
AMZN   144.93 (+1.22%)
TSLA   922.06 (-0.64%)
NVDA   188.87 (-0.76%)
NIO   20.91 (-1.83%)
BABA   92.83 (-1.45%)
AMD   99.89 (-1.11%)
MU   64.14 (-0.87%)
T   18.66 (+1.47%)
CGC   3.80 (-0.52%)
F   16.56 (+1.47%)
GE   80.19 (+0.48%)
DIS   125.25 (+0.80%)
AMC   24.77 (+2.31%)
PYPL   101.84 (+0.33%)
PFE   49.90 (+0.30%)
NFLX   246.64 (-0.99%)
QQQ   332.15 (-0.27%)
AAPL   172.76 (-0.25%)
MSFT   292.24 (-0.42%)
META   179.16 (-0.96%)
GOOGL   121.82 (-0.21%)
AMZN   144.93 (+1.22%)
TSLA   922.06 (-0.64%)
NVDA   188.87 (-0.76%)
NIO   20.91 (-1.83%)
BABA   92.83 (-1.45%)
AMD   99.89 (-1.11%)
MU   64.14 (-0.87%)
T   18.66 (+1.47%)
CGC   3.80 (-0.52%)
F   16.56 (+1.47%)
GE   80.19 (+0.48%)
DIS   125.25 (+0.80%)
AMC   24.77 (+2.31%)
PYPL   101.84 (+0.33%)
PFE   49.90 (+0.30%)
NFLX   246.64 (-0.99%)
QQQ   332.15 (-0.27%)
AAPL   172.76 (-0.25%)
MSFT   292.24 (-0.42%)
META   179.16 (-0.96%)
GOOGL   121.82 (-0.21%)
AMZN   144.93 (+1.22%)
TSLA   922.06 (-0.64%)
NVDA   188.87 (-0.76%)
NIO   20.91 (-1.83%)
BABA   92.83 (-1.45%)
AMD   99.89 (-1.11%)
MU   64.14 (-0.87%)
T   18.66 (+1.47%)
CGC   3.80 (-0.52%)
F   16.56 (+1.47%)
GE   80.19 (+0.48%)
DIS   125.25 (+0.80%)
AMC   24.77 (+2.31%)
PYPL   101.84 (+0.33%)
PFE   49.90 (+0.30%)
NFLX   246.64 (-0.99%)
NYSE:PEN

Penumbra - PEN Stock Forecast, Price & News

$170.14
-4.55 (-2.60%)
(As of 08/16/2022 12:53 PM ET)
Add
Compare
Today's Range
$167.81
$171.77
50-Day Range
$116.09
$174.69
52-Week Range
$114.86
$293.20
Volume
4,261 shs
Average Volume
505,527 shs
Market Capitalization
$6.45 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$218.78

Penumbra MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.89 Rating Score
Upside/​Downside
29.5% Upside
$218.78 Price Target
Short Interest
Healthy
5.73% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.89
Upright™ Environmental Score
News Sentiment
0.08mentions of Penumbra in the last 14 days
Based on 4 Articles This Week
Insider Trading
Selling Shares
$57,968 Sold Last Quarter
Proj. Earnings Growth
352.00%
From $0.25 to $1.13 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.53 out of 5 stars

Medical Sector

181st out of 1,124 stocks

Surgical & Medical Instruments Industry

14th out of 113 stocks

PEN stock logo

About Penumbra (NYSE:PEN) Stock

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Wall Street Analyst Weigh In

PEN has been the subject of a number of recent research reports. William Blair reissued an "outperform" rating on shares of Penumbra in a research report on Tuesday, May 3rd. Citigroup decreased their target price on Penumbra from $280.00 to $220.00 in a research report on Tuesday, May 17th. Canaccord Genuity Group decreased their target price on Penumbra from $244.00 to $189.00 and set a "buy" rating for the company in a research report on Friday, August 5th. BTIG Research cut their price target on Penumbra from $272.00 to $213.00 and set a "buy" rating for the company in a report on Monday, July 18th. Finally, Wells Fargo & Company cut their price target on Penumbra from $321.00 to $265.00 in a report on Wednesday, May 4th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, Penumbra has a consensus rating of "Moderate Buy" and an average price target of $218.78.

Penumbra Price Performance

NYSE:PEN traded up $2.67 during trading hours on Monday, hitting $174.69. 171,439 shares of the company's stock traded hands, compared to its average volume of 302,808. The firm has a market cap of $6.62 billion, a P/E ratio of -335.53 and a beta of 0.73. Penumbra has a 52 week low of $114.86 and a 52 week high of $293.20. The business's fifty day simple moving average is $134.43 and its two-hundred day simple moving average is $172.44. The company has a quick ratio of 2.90, a current ratio of 4.93 and a debt-to-equity ratio of 0.03.

Penumbra (NYSE:PEN - Get Rating) last posted its quarterly earnings data on Thursday, August 4th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.06) by $0.07. Penumbra had a positive return on equity of 0.97% and a negative net margin of 2.40%. The company had revenue of $208.30 million during the quarter, compared to analyst estimates of $206.24 million. During the same quarter last year, the company earned $0.21 earnings per share. The firm's quarterly revenue was up 13.0% on a year-over-year basis. On average, research analysts anticipate that Penumbra will post 0.25 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Penumbra news, Director Thomas Wilder sold 248 shares of Penumbra stock in a transaction dated Tuesday, July 5th. The stock was sold at an average price of $123.64, for a total transaction of $30,662.72. Following the completion of the sale, the director now owns 462 shares of the company's stock, valued at $57,121.68. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders sold a total of 451 shares of company stock valued at $57,968 over the last 90 days. Insiders own 5.50% of the company's stock.

Receive PEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

PEN Stock News Headlines

Penumbra (NYSE:PEN) Trading Up 10.5% After Strong Earnings
Penumbra (NYSE:PEN) Shares Up 10.5% on Strong Earnings
Penumbra (PEN) to Release Earnings on Thursday
See More Headlines
Receive PEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Penumbra and its competitors with MarketBeat's FREE daily newsletter.

PEN Company Calendar

Last Earnings
8/04/2022
Today
8/16/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Employees
3,800
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$218.78
High Stock Price Forecast
$300.00
Low Stock Price Forecast
$163.00
Forecasted Upside/Downside
+28.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Net Income
$5.28 million
Pretax Margin
-4.89%

Debt

Sales & Book Value

Annual Sales
$747.59 million
Cash Flow
$1.13 per share
Book Value
$25.53 per share

Miscellaneous

Free Float
35,804,000
Market Cap
$6.45 billion
Optionable
Optionable
Beta
0.73

Key Executives














PEN Stock - Frequently Asked Questions

Should I buy or sell Penumbra stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Penumbra in the last year. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PEN shares.
View PEN analyst ratings
or view top-rated stocks.

What is Penumbra's stock price forecast for 2022?

9 brokers have issued 12 month price targets for Penumbra's stock. Their PEN share price forecasts range from $163.00 to $300.00. On average, they anticipate the company's share price to reach $218.78 in the next year. This suggests a possible upside of 25.2% from the stock's current price.
View analysts price targets for PEN
or view top-rated stocks among Wall Street analysts.

How have PEN shares performed in 2022?

Penumbra's stock was trading at $287.32 on January 1st, 2022. Since then, PEN stock has decreased by 39.2% and is now trading at $174.69.
View the best growth stocks for 2022 here
.

When is Penumbra's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our PEN earnings forecast
.

How were Penumbra's earnings last quarter?

Penumbra, Inc. (NYSE:PEN) issued its quarterly earnings results on Thursday, August, 4th. The company reported $0.01 EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $0.07. The business earned $208.30 million during the quarter, compared to the consensus estimate of $206.24 million. Penumbra had a negative net margin of 2.40% and a positive trailing twelve-month return on equity of 0.97%. Penumbra's revenue was up 13.0% on a year-over-year basis. During the same quarter last year, the business earned $0.21 EPS.

What guidance has Penumbra issued on next quarter's earnings?

Penumbra updated its FY 2022 earnings guidance on Thursday, August, 11th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $860.00 million-$875.00 million, compared to the consensus revenue estimate of $869.01 million.

What is Adam Elsesser's approval rating as Penumbra's CEO?

57 employees have rated Penumbra Chief Executive Officer Adam Elsesser on Glassdoor.com. Adam Elsesser has an approval rating of 88% among the company's employees.

What other stocks do shareholders of Penumbra own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Penumbra investors own include NVIDIA (NVDA), Intuitive Surgical (ISRG), AbbVie (ABBV), Tesla (TSLA), Alibaba Group (BABA), Johnson & Johnson (JNJ), Netflix (NFLX), UnitedHealth Group (UNH), Boeing (BA) and DexCom (DXCM).

What is Penumbra's stock symbol?

Penumbra trades on the New York Stock Exchange (NYSE) under the ticker symbol "PEN."

Who are Penumbra's major shareholders?

Penumbra's stock is owned by a variety of institutional and retail investors. Top institutional investors include FMR LLC (14.92%), Baillie Gifford & Co. (3.38%), Clearbridge Investments LLC (2.69%), William Blair Investment Management LLC (2.58%), State Street Corp (2.56%) and Northern Trust Corp (0.69%). Insiders that own company stock include Adam Elsesser, Arani Bose, Bridget O'rourke, Coyne David, Don W Kassing, Don W Kassing, Harpreet Grewal, James Robert Pray, Johanna Roberts, Lynn Rothman, Sridhar Kosaraju, Surbhi Sarna and Thomas Wilder.
View institutional ownership trends
.

How do I buy shares of Penumbra?

Shares of PEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Penumbra's stock price today?

One share of PEN stock can currently be purchased for approximately $174.69.

How much money does Penumbra make?

Penumbra (NYSE:PEN) has a market capitalization of $6.62 billion and generates $747.59 million in revenue each year. The company earns $5.28 million in net income (profit) each year or ($0.52) on an earnings per share basis.

How many employees does Penumbra have?

The company employs 3,800 workers across the globe.

How can I contact Penumbra?

Penumbra's mailing address is One Penumbra Place, Alameda CA, 94502. The official website for the company is www.penumbrainc.com. The company can be reached via phone at (510) 748-3200, via email at investors@penumbrainc.com, or via fax at 510-748-3232.

This page (NYSE:PEN) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.